ES2791186T3 - Triazoles como inhibidores de receptores NR2B - Google Patents
Triazoles como inhibidores de receptores NR2B Download PDFInfo
- Publication number
- ES2791186T3 ES2791186T3 ES15777754T ES15777754T ES2791186T3 ES 2791186 T3 ES2791186 T3 ES 2791186T3 ES 15777754 T ES15777754 T ES 15777754T ES 15777754 T ES15777754 T ES 15777754T ES 2791186 T3 ES2791186 T3 ES 2791186T3
- Authority
- ES
- Spain
- Prior art keywords
- phenyl
- ylmethyl
- triazole
- imidazol
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010038912 Retinoid X Receptors Proteins 0.000 title description 16
- 150000003852 triazoles Chemical class 0.000 title description 6
- 108091006082 receptor inhibitors Proteins 0.000 title description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 claims abstract description 222
- 150000001875 compounds Chemical class 0.000 claims abstract description 142
- 150000003839 salts Chemical class 0.000 claims abstract description 76
- 125000001424 substituent group Chemical group 0.000 claims abstract description 75
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 74
- 150000002367 halogens Chemical class 0.000 claims abstract description 69
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 64
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 55
- 239000012453 solvate Substances 0.000 claims abstract description 36
- 150000001204 N-oxides Chemical class 0.000 claims abstract description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 30
- 239000001257 hydrogen Substances 0.000 claims abstract description 30
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 25
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims abstract description 19
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 10
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 7
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 6
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 5
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 32
- -1 3,5-dicyclopropyl- [1,2,4] triazol-1-ylmethyl Chemical group 0.000 claims description 107
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 69
- 208000035475 disorder Diseases 0.000 claims description 40
- 201000010099 disease Diseases 0.000 claims description 29
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 208000002193 Pain Diseases 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 102000005962 receptors Human genes 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 11
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 10
- 206010015037 epilepsy Diseases 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 208000019022 Mood disease Diseases 0.000 claims description 7
- 208000016285 Movement disease Diseases 0.000 claims description 7
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- 230000036407 pain Effects 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 208000027520 Somatoform disease Diseases 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 238000011161 development Methods 0.000 claims description 5
- 208000013403 hyperactivity Diseases 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 claims description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 4
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- OBJSITFIPOKILU-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)C)F Chemical compound FC(OC=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)C)F OBJSITFIPOKILU-UHFFFAOYSA-N 0.000 claims description 4
- 101710195187 Glutamate receptor ionotropic, NMDA 2B Proteins 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 208000029560 autism spectrum disease Diseases 0.000 claims description 4
- 230000003542 behavioural effect Effects 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 206010008118 cerebral infarction Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 230000001667 episodic effect Effects 0.000 claims description 4
- 208000024714 major depressive disease Diseases 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- 230000001314 paroxysmal effect Effects 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- CEAOOXKEMXDLAB-UHFFFAOYSA-N C(CCC)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC=C(C=C1)Cl Chemical compound C(CCC)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC=C(C=C1)Cl CEAOOXKEMXDLAB-UHFFFAOYSA-N 0.000 claims description 3
- OCWFBNMIXTWOIS-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C OCWFBNMIXTWOIS-UHFFFAOYSA-N 0.000 claims description 3
- NRWRQBPXPZXDGL-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C(C)C Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C(C)C NRWRQBPXPZXDGL-UHFFFAOYSA-N 0.000 claims description 3
- UHCWOUZOICIRGT-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)CC Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)CC UHCWOUZOICIRGT-UHFFFAOYSA-N 0.000 claims description 3
- AYJDATHUPMMOSP-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)CCC Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)CCC AYJDATHUPMMOSP-UHFFFAOYSA-N 0.000 claims description 3
- IVDHBJSENGBWTH-UHFFFAOYSA-N ClC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC=C(C=C1)Cl Chemical compound ClC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC=C(C=C1)Cl IVDHBJSENGBWTH-UHFFFAOYSA-N 0.000 claims description 3
- QULVTNJBHGMPJK-UHFFFAOYSA-N FC(C)(F)C=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)CCO Chemical compound FC(C)(F)C=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)CCO QULVTNJBHGMPJK-UHFFFAOYSA-N 0.000 claims description 3
- UEBVHKXENWPKIG-UHFFFAOYSA-N FC(C=1C=C(C=C(C=1)F)N1N=NC(=C1)CN1C(=NC=C1)CCF)F Chemical compound FC(C=1C=C(C=C(C=1)F)N1N=NC(=C1)CN1C(=NC=C1)CCF)F UEBVHKXENWPKIG-UHFFFAOYSA-N 0.000 claims description 3
- XEAHOSRXLJEYBK-UHFFFAOYSA-N FC(C=1C=C(C=C(C=1)F)N1N=NC(=C1)CN1C(=NC=C1)CCO)F Chemical compound FC(C=1C=C(C=C(C=1)F)N1N=NC(=C1)CN1C(=NC=C1)CCO)F XEAHOSRXLJEYBK-UHFFFAOYSA-N 0.000 claims description 3
- MVPGLWBEKNSVHN-UHFFFAOYSA-N OCC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC=C(C=C1)Cl Chemical compound OCC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC=C(C=C1)Cl MVPGLWBEKNSVHN-UHFFFAOYSA-N 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 201000009916 Postpartum depression Diseases 0.000 claims description 3
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 208000018300 basal ganglia disease Diseases 0.000 claims description 3
- 230000000926 neurological effect Effects 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- AQLRWJVRJUSCJS-UHFFFAOYSA-N 1-[[1-(4-chlorophenyl)triazol-4-yl]methyl]-3,5-dimethyl-1,2,4-triazole Chemical compound N1=C(C)N=C(C)N1CC1=CN(C=2C=CC(Cl)=CC=2)N=N1 AQLRWJVRJUSCJS-UHFFFAOYSA-N 0.000 claims description 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- NNARYJXWYNWMSY-UHFFFAOYSA-N C(C)(C)(C)C1=NC=NN1CC=1N=NN(C=1)C1=CC=C(C=C1)Cl Chemical compound C(C)(C)(C)C1=NC=NN1CC=1N=NN(C=1)C1=CC=C(C=C1)Cl NNARYJXWYNWMSY-UHFFFAOYSA-N 0.000 claims description 2
- WTTBNWBKWZDRPV-UHFFFAOYSA-N C(C)(C)(C)C1=NN(C=N1)CC=1N=NN(C=1)C1=CC=C(C=C1)Cl Chemical compound C(C)(C)(C)C1=NN(C=N1)CC=1N=NN(C=1)C1=CC=C(C=C1)Cl WTTBNWBKWZDRPV-UHFFFAOYSA-N 0.000 claims description 2
- QSKZBFJMOFMZSF-UHFFFAOYSA-N CC1=NC=CN1CC1=CN(N=N1)C1=CC(C(F)F)=C(F)C=C1 Chemical compound CC1=NC=CN1CC1=CN(N=N1)C1=CC(C(F)F)=C(F)C=C1 QSKZBFJMOFMZSF-UHFFFAOYSA-N 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- BHASKRVNSLNZGW-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C1CC1)OC(F)F Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C1CC1)OC(F)F BHASKRVNSLNZGW-UHFFFAOYSA-N 0.000 claims description 2
- RPRRSXXASCSWCX-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)CC)OC(F)F Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)CC)OC(F)F RPRRSXXASCSWCX-UHFFFAOYSA-N 0.000 claims description 2
- FMXPLHPTIXIQOD-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C(=O)C1=CC=C(C=C1)C Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C(=O)C1=CC=C(C=C1)C FMXPLHPTIXIQOD-UHFFFAOYSA-N 0.000 claims description 2
- TXAHJZVCNFFEJR-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1)C Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1)C TXAHJZVCNFFEJR-UHFFFAOYSA-N 0.000 claims description 2
- PWVKLWNAGDSQLN-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1)C(C)C Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1)C(C)C PWVKLWNAGDSQLN-UHFFFAOYSA-N 0.000 claims description 2
- CAIRHTFTLPIFQU-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1)C(F)(F)F Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1)C(F)(F)F CAIRHTFTLPIFQU-UHFFFAOYSA-N 0.000 claims description 2
- FYLLXYYSVQPAKZ-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1)C1CC1 Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1)C1CC1 FYLLXYYSVQPAKZ-UHFFFAOYSA-N 0.000 claims description 2
- CWHJIHOWGGKGEA-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1)C1CCC1 Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1)C1CCC1 CWHJIHOWGGKGEA-UHFFFAOYSA-N 0.000 claims description 2
- AQRMSNKJMMOWNY-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1)C1CCCC1 Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1)C1CCCC1 AQRMSNKJMMOWNY-UHFFFAOYSA-N 0.000 claims description 2
- HRQZQCFVMLFYSB-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1)CC Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1)CC HRQZQCFVMLFYSB-UHFFFAOYSA-N 0.000 claims description 2
- RZCIDOWEQOSVFU-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1)CCC Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1)CCC RZCIDOWEQOSVFU-UHFFFAOYSA-N 0.000 claims description 2
- BGVIDOSBQYMVSL-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1C)C1CCC1 Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1C)C1CCC1 BGVIDOSBQYMVSL-UHFFFAOYSA-N 0.000 claims description 2
- KTERBHGAOPMQME-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1C1CCC1)C Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=C(N=C1C1CCC1)C KTERBHGAOPMQME-UHFFFAOYSA-N 0.000 claims description 2
- AMYCLBLRVRIJGO-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=CN=C1C Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=CN=C1C AMYCLBLRVRIJGO-UHFFFAOYSA-N 0.000 claims description 2
- DSHSWXIKZMKFMX-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=CN=C1C(C)C Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=CN=C1C(C)C DSHSWXIKZMKFMX-UHFFFAOYSA-N 0.000 claims description 2
- OETSVHHBHCIQTP-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=CN=C1C1CC1 Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=CN=C1C1CC1 OETSVHHBHCIQTP-UHFFFAOYSA-N 0.000 claims description 2
- QKBPERVPIARHRO-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=CN=C1C1CCC1 Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=CN=C1C1CCC1 QKBPERVPIARHRO-UHFFFAOYSA-N 0.000 claims description 2
- FDBRNTUVWGVIAY-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=CN=C1C1CCCC1 Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=CN=C1C1CCCC1 FDBRNTUVWGVIAY-UHFFFAOYSA-N 0.000 claims description 2
- VKYQAXYBRHJTAL-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=CN=C1CC Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=CN=C1CC VKYQAXYBRHJTAL-UHFFFAOYSA-N 0.000 claims description 2
- IWNKFQATMQELSV-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=CN=C1CCC Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1N=CN=C1CCC IWNKFQATMQELSV-UHFFFAOYSA-N 0.000 claims description 2
- NBDNSJRTVZQEOU-UHFFFAOYSA-N ClC=1C=C(C=CC=1Cl)N1N=NC(=C1)CN1C(=NC2=C1C=CC=C2)C Chemical compound ClC=1C=C(C=CC=1Cl)N1N=NC(=C1)CN1C(=NC2=C1C=CC=C2)C NBDNSJRTVZQEOU-UHFFFAOYSA-N 0.000 claims description 2
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- OCGOMHKIACWSMG-UHFFFAOYSA-N FC(C=1C=C(C=C(C=1)F)N1N=NC(=C1)CN1C(=NC=C1)C)F Chemical compound FC(C=1C=C(C=C(C=1)F)N1N=NC(=C1)CN1C(=NC=C1)C)F OCGOMHKIACWSMG-UHFFFAOYSA-N 0.000 claims description 2
- XCUYCJFGWDLGRI-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)N1N=NC(=C1)CC1=NNC=C1)F Chemical compound FC(C=1C=C(C=CC=1F)N1N=NC(=C1)CC1=NNC=C1)F XCUYCJFGWDLGRI-UHFFFAOYSA-N 0.000 claims description 2
- CQYRYSJJBAIWRQ-UHFFFAOYSA-N FC(OC=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)CCO)F Chemical compound FC(OC=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)CCO)F CQYRYSJJBAIWRQ-UHFFFAOYSA-N 0.000 claims description 2
- 206010019196 Head injury Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000020358 Learning disease Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- SRQPKXBAGJDKMJ-UHFFFAOYSA-N NC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)C(F)F)F Chemical compound NC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)C(F)F)F SRQPKXBAGJDKMJ-UHFFFAOYSA-N 0.000 claims description 2
- ZCROGTMUHYRBRR-UHFFFAOYSA-N NC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)Cl)C(F)F Chemical compound NC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)Cl)C(F)F ZCROGTMUHYRBRR-UHFFFAOYSA-N 0.000 claims description 2
- UZRIQFGTVHJEPZ-UHFFFAOYSA-N NC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)F)C(F)F Chemical compound NC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)F)C(F)F UZRIQFGTVHJEPZ-UHFFFAOYSA-N 0.000 claims description 2
- XNKTWVPPPLRTKJ-UHFFFAOYSA-N NC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=CC(=C1)C(F)F)F Chemical compound NC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=CC(=C1)C(F)F)F XNKTWVPPPLRTKJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000037581 Persistent Infection Diseases 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 201000003723 learning disability Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 208000012672 seasonal affective disease Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims 3
- ABOXKYVSSWHNON-UHFFFAOYSA-N C(C)(C)(C)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)Cl)Cl Chemical compound C(C)(C)(C)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)Cl)Cl ABOXKYVSSWHNON-UHFFFAOYSA-N 0.000 claims 2
- KHTCVPAURHYMJW-UHFFFAOYSA-N C(C)(C)(C)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC=C(C=C1)Cl Chemical compound C(C)(C)(C)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC=C(C=C1)Cl KHTCVPAURHYMJW-UHFFFAOYSA-N 0.000 claims 2
- FABOZFZSWJBLAK-UHFFFAOYSA-N C(CCC)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)Cl)Cl Chemical compound C(CCC)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)Cl)Cl FABOZFZSWJBLAK-UHFFFAOYSA-N 0.000 claims 2
- YUDVHEROTXDJBH-UHFFFAOYSA-N C1(CCC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)Cl)Cl Chemical compound C1(CCC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)Cl)Cl YUDVHEROTXDJBH-UHFFFAOYSA-N 0.000 claims 2
- NTXPVEQQFPXEPU-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C)OC(F)F Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C)OC(F)F NTXPVEQQFPXEPU-UHFFFAOYSA-N 0.000 claims 2
- UCXUHYULIWVCHH-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C1CC1 Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C1CC1 UCXUHYULIWVCHH-UHFFFAOYSA-N 0.000 claims 2
- AJGOWAAIQPCIPM-UHFFFAOYSA-N ClC=1C=C(C=CC=1Cl)N1N=NC(=C1)CN1C(=NC=C1)C(C)C Chemical compound ClC=1C=C(C=CC=1Cl)N1N=NC(=C1)CN1C(=NC=C1)C(C)C AJGOWAAIQPCIPM-UHFFFAOYSA-N 0.000 claims 2
- WAGGNWZFAHXBMP-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)CCO)F Chemical compound FC(C=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)CCO)F WAGGNWZFAHXBMP-UHFFFAOYSA-N 0.000 claims 2
- WKSZMTYLSCHZID-UHFFFAOYSA-N NC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)F)C(C)(F)F Chemical compound NC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)F)C(C)(F)F WKSZMTYLSCHZID-UHFFFAOYSA-N 0.000 claims 2
- 108010054200 NR2B NMDA receptor Proteins 0.000 claims 2
- DZEGAUUMJVVSNN-UHFFFAOYSA-N C(C)(C)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=CC=C1)OC(F)(F)F Chemical compound C(C)(C)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=CC=C1)OC(F)(F)F DZEGAUUMJVVSNN-UHFFFAOYSA-N 0.000 claims 1
- ZUBNWKBIEHKLQD-UHFFFAOYSA-N C(C)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=CC=C1)OC(F)(F)F Chemical compound C(C)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=CC=C1)OC(F)(F)F ZUBNWKBIEHKLQD-UHFFFAOYSA-N 0.000 claims 1
- VTFRNZQXDOHSFI-UHFFFAOYSA-N C(CCC)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)F)Cl Chemical compound C(CCC)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)F)Cl VTFRNZQXDOHSFI-UHFFFAOYSA-N 0.000 claims 1
- BCMMYCCUZMUCKE-UHFFFAOYSA-N C1(CC1)C=1C=C(C=CC=1)N1N=NC(=C1)CN1C(=NC=C1)C Chemical compound C1(CC1)C=1C=C(C=CC=1)N1N=NC(=C1)CN1C(=NC=C1)C BCMMYCCUZMUCKE-UHFFFAOYSA-N 0.000 claims 1
- RZJJYMUPIPAFHM-UHFFFAOYSA-N C1(CC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=C(C=C(C=C1)Cl)Cl Chemical compound C1(CC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=C(C=C(C=C1)Cl)Cl RZJJYMUPIPAFHM-UHFFFAOYSA-N 0.000 claims 1
- VYUWAHTYQGQTNF-UHFFFAOYSA-N C1(CC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=C(C=C(C=C1)F)OC Chemical compound C1(CC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=C(C=C(C=C1)F)OC VYUWAHTYQGQTNF-UHFFFAOYSA-N 0.000 claims 1
- UZACFXZVMOVAMD-UHFFFAOYSA-N C1(CC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)C)F Chemical compound C1(CC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)C)F UZACFXZVMOVAMD-UHFFFAOYSA-N 0.000 claims 1
- IEGRHOUALWXAMI-UHFFFAOYSA-N C1(CC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)Cl)Cl Chemical compound C1(CC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)Cl)Cl IEGRHOUALWXAMI-UHFFFAOYSA-N 0.000 claims 1
- BTLPJWLNOBZJLX-UHFFFAOYSA-N C1(CC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)F)C Chemical compound C1(CC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)F)C BTLPJWLNOBZJLX-UHFFFAOYSA-N 0.000 claims 1
- XRNXEVVICQRAAE-UHFFFAOYSA-N C1(CC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)F)C(F)F Chemical compound C1(CC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)F)C(F)F XRNXEVVICQRAAE-UHFFFAOYSA-N 0.000 claims 1
- IECCSHSCJSNUFX-UHFFFAOYSA-N C1(CC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=CC=C1)C(F)(F)F Chemical compound C1(CC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=CC=C1)C(F)(F)F IECCSHSCJSNUFX-UHFFFAOYSA-N 0.000 claims 1
- BINRGTLWUGYJBP-UHFFFAOYSA-N C1(CC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=CC=C1)OC(F)(F)F Chemical compound C1(CC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=CC=C1)OC(F)(F)F BINRGTLWUGYJBP-UHFFFAOYSA-N 0.000 claims 1
- NMIQLTRGPMQQII-UHFFFAOYSA-N C1(CC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC=C(C=C1)C(F)(F)F Chemical compound C1(CC1)C=1N(C=CN=1)CC=1N=NN(C=1)C1=CC=C(C=C1)C(F)(F)F NMIQLTRGPMQQII-UHFFFAOYSA-N 0.000 claims 1
- PVCPERVVEUJKJP-UHFFFAOYSA-N CC(C)(C)C1=NC=CN1CC1=CN(N=N1)C1=CC=C(F)C(=C1)C(F)F Chemical compound CC(C)(C)C1=NC=CN1CC1=CN(N=N1)C1=CC=C(F)C(=C1)C(F)F PVCPERVVEUJKJP-UHFFFAOYSA-N 0.000 claims 1
- VFTFBBYRZOXORC-UHFFFAOYSA-N CC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=CC=C1)C(F)(F)F Chemical compound CC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=CC=C1)C(F)(F)F VFTFBBYRZOXORC-UHFFFAOYSA-N 0.000 claims 1
- PSNQKKDWPZLWKY-UHFFFAOYSA-N CC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=CC=C1)OC(F)(F)F Chemical compound CC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=CC=C1)OC(F)(F)F PSNQKKDWPZLWKY-UHFFFAOYSA-N 0.000 claims 1
- BLCNKRJMNGQWJU-UHFFFAOYSA-N CC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC=C(C=C1)C(F)(F)F Chemical compound CC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC=C(C=C1)C(F)(F)F BLCNKRJMNGQWJU-UHFFFAOYSA-N 0.000 claims 1
- FTODECXLANNKPC-UHFFFAOYSA-N CS(=O)(=O)C=1C=C(C=CC=1)N1N=NC(=C1)CN1C(=NC=C1)C Chemical compound CS(=O)(=O)C=1C=C(C=CC=1)N1N=NC(=C1)CN1C(=NC=C1)C FTODECXLANNKPC-UHFFFAOYSA-N 0.000 claims 1
- PNOCWPPPUIQTEQ-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C(C)C)C Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C(C)C)C PNOCWPPPUIQTEQ-UHFFFAOYSA-N 0.000 claims 1
- PEDNWEQKMIWGBJ-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C(C)C)C(F)F Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C(C)C)C(F)F PEDNWEQKMIWGBJ-UHFFFAOYSA-N 0.000 claims 1
- OSODAZMEELVOGC-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C(C)C)OC(F)F Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C(C)C)OC(F)F OSODAZMEELVOGC-UHFFFAOYSA-N 0.000 claims 1
- UJRJRHMCPMPBNM-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C)C Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C)C UJRJRHMCPMPBNM-UHFFFAOYSA-N 0.000 claims 1
- DRHMCKZRSIYNSH-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C)C(F)(F)F Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C)C(F)(F)F DRHMCKZRSIYNSH-UHFFFAOYSA-N 0.000 claims 1
- QLHBDCCSPGVPTO-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C)C(F)F Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C)C(F)F QLHBDCCSPGVPTO-UHFFFAOYSA-N 0.000 claims 1
- FMTUKULXLDFHHK-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C)F Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C)F FMTUKULXLDFHHK-UHFFFAOYSA-N 0.000 claims 1
- LCRLHAYDJUFDBS-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C1CC1)C Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C1CC1)C LCRLHAYDJUFDBS-UHFFFAOYSA-N 0.000 claims 1
- UULWSVSDBXUUNT-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C1CC1)C(F)(F)F Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C1CC1)C(F)(F)F UULWSVSDBXUUNT-UHFFFAOYSA-N 0.000 claims 1
- JLSQSDCBSROECG-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C1CC1)C(F)F Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C1CC1)C(F)F JLSQSDCBSROECG-UHFFFAOYSA-N 0.000 claims 1
- BJBDOPNIPHEBTL-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C1CC1)F Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C1CC1)F BJBDOPNIPHEBTL-UHFFFAOYSA-N 0.000 claims 1
- HQQFCWPHPRSGTH-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)CC)C Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)CC)C HQQFCWPHPRSGTH-UHFFFAOYSA-N 0.000 claims 1
- CIAAWOPCBYSYLC-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)CC)C(F)F Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)CC)C(F)F CIAAWOPCBYSYLC-UHFFFAOYSA-N 0.000 claims 1
- KOJCWZJFTKOHIH-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)CCF)C Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)CCF)C KOJCWZJFTKOHIH-UHFFFAOYSA-N 0.000 claims 1
- QGHUYWCWQWJAPH-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)CCO)C Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)CCO)C QGHUYWCWQWJAPH-UHFFFAOYSA-N 0.000 claims 1
- BRINTJVXMVTOJY-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)N)OC(F)F Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)N)OC(F)F BRINTJVXMVTOJY-UHFFFAOYSA-N 0.000 claims 1
- VYRSMGXIQJIWHO-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)N1N=NC(=C1)CN1C(=NC=C1)C Chemical compound ClC1=C(C=CC(=C1)Cl)N1N=NC(=C1)CN1C(=NC=C1)C VYRSMGXIQJIWHO-UHFFFAOYSA-N 0.000 claims 1
- LMZPNUTXBLCHOF-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=NC(=C1)CN1C(=NN=C1)C Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1C(=NN=C1)C LMZPNUTXBLCHOF-UHFFFAOYSA-N 0.000 claims 1
- ZZKGILMYXMDXEH-UHFFFAOYSA-N ClC=1C=C(C=CC=1Cl)N1N=NC(=C1)CN1C(=NC=C1)C Chemical compound ClC=1C=C(C=CC=1Cl)N1N=NC(=C1)CN1C(=NC=C1)C ZZKGILMYXMDXEH-UHFFFAOYSA-N 0.000 claims 1
- PNPKQVICELDSLM-UHFFFAOYSA-N ClC=1C=C(C=CC=1Cl)N1N=NC(=C1)CN1C(=NC=C1)CCF Chemical compound ClC=1C=C(C=CC=1Cl)N1N=NC(=C1)CN1C(=NC=C1)CCF PNPKQVICELDSLM-UHFFFAOYSA-N 0.000 claims 1
- RIWYADOJEYZZRZ-UHFFFAOYSA-N ClC=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)C Chemical compound ClC=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)C RIWYADOJEYZZRZ-UHFFFAOYSA-N 0.000 claims 1
- LSZVDBKEFVBAEY-UHFFFAOYSA-N ClC=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)C1CC1 Chemical compound ClC=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)C1CC1 LSZVDBKEFVBAEY-UHFFFAOYSA-N 0.000 claims 1
- JFZBXZHTGAUVGD-UHFFFAOYSA-N ClC=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)CC Chemical compound ClC=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)CC JFZBXZHTGAUVGD-UHFFFAOYSA-N 0.000 claims 1
- WMFPPBDLJCGXMI-UHFFFAOYSA-N ClC=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)CCC Chemical compound ClC=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)CCC WMFPPBDLJCGXMI-UHFFFAOYSA-N 0.000 claims 1
- 208000027776 Extrapyramidal disease Diseases 0.000 claims 1
- RHCWEINUWQCGDI-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)C(C)C)F Chemical compound FC(C=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)C(C)C)F RHCWEINUWQCGDI-UHFFFAOYSA-N 0.000 claims 1
- APCKLHZSVVXCSJ-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)CCC)F Chemical compound FC(C=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)CCC)F APCKLHZSVVXCSJ-UHFFFAOYSA-N 0.000 claims 1
- ILHXDJNKXGVDCA-UHFFFAOYSA-N FC(C=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)CCCC)F Chemical compound FC(C=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)CCCC)F ILHXDJNKXGVDCA-UHFFFAOYSA-N 0.000 claims 1
- SUUBNQYDSCYRFB-UHFFFAOYSA-N FC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C)C Chemical compound FC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C)C SUUBNQYDSCYRFB-UHFFFAOYSA-N 0.000 claims 1
- VAYNXGJHBAWNOK-UHFFFAOYSA-N FC1=CC(=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C)OC Chemical compound FC1=CC(=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)C)OC VAYNXGJHBAWNOK-UHFFFAOYSA-N 0.000 claims 1
- VNHDHBHZGUTBRW-UHFFFAOYSA-N FC=1C=C(C=CC=1C)N1N=NC(=C1)CN1C(=NC=C1)C Chemical compound FC=1C=C(C=CC=1C)N1N=NC(=C1)CN1C(=NC=C1)C VNHDHBHZGUTBRW-UHFFFAOYSA-N 0.000 claims 1
- KLOSGRVATVPBIQ-UHFFFAOYSA-N FCCC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=CC=C1)S(=O)(=O)C Chemical compound FCCC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=CC=C1)S(=O)(=O)C KLOSGRVATVPBIQ-UHFFFAOYSA-N 0.000 claims 1
- HRJGAGOKRFPCOH-UHFFFAOYSA-N OCCC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)Cl)Cl Chemical compound OCCC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=C(C=C1)Cl)Cl HRJGAGOKRFPCOH-UHFFFAOYSA-N 0.000 claims 1
- JOCVQBDURVHERC-UHFFFAOYSA-N OCCC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=CC=C1)S(=O)(=O)C Chemical compound OCCC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC(=CC=C1)S(=O)(=O)C JOCVQBDURVHERC-UHFFFAOYSA-N 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 description 53
- 239000000203 mixture Substances 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000012528 membrane Substances 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 239000002253 acid Substances 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 239000007983 Tris buffer Substances 0.000 description 13
- 125000004429 atom Chemical group 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- XYYXDARQOHWBPO-UHFFFAOYSA-N 3,5-dimethyl-1h-1,2,4-triazole Chemical compound CC1=NNC(C)=N1 XYYXDARQOHWBPO-UHFFFAOYSA-N 0.000 description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 11
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 238000003818 flash chromatography Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 7
- 208000014094 Dystonic disease Diseases 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 7
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 7
- 102000034570 NR1 subfamily Human genes 0.000 description 7
- 108020001305 NR1 subfamily Proteins 0.000 description 7
- 229930195712 glutamate Natural products 0.000 description 7
- 229960003998 ifenprodil Drugs 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000003176 neuroleptic agent Substances 0.000 description 7
- 230000000701 neuroleptic effect Effects 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 230000009870 specific binding Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 208000002877 Epileptic Syndromes Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 208000010118 dystonia Diseases 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- 150000002460 imidazoles Chemical class 0.000 description 6
- 150000007522 mineralic acids Chemical class 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 235000011181 potassium carbonates Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- JEUPWQVILXWUFD-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)ethanol Chemical compound OCCC1=NC=CN1 JEUPWQVILXWUFD-UHFFFAOYSA-N 0.000 description 5
- VVXFDFQEIRGULC-UHFFFAOYSA-N 2-fluoro-5-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(F)C(C=O)=C1 VVXFDFQEIRGULC-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 208000000094 Chronic Pain Diseases 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 5
- 208000020401 Depressive disease Diseases 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 206010036105 Polyneuropathy Diseases 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 208000005298 acute pain Diseases 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000002964 excitative effect Effects 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000004220 glutamic acid Chemical group 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 230000007824 polyneuropathy Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008117 stearic acid Chemical group 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 3
- SUVIQAGOOXDQMH-UHFFFAOYSA-N 4-chloro-3-(difluoromethoxy)aniline Chemical compound NC1=CC=C(Cl)C(OC(F)F)=C1 SUVIQAGOOXDQMH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 0 Cc1c(*)[n](*)nc1* Chemical compound Cc1c(*)[n](*)nc1* 0.000 description 3
- OMQQLDITRYIEHZ-UHFFFAOYSA-N ClC=1C=C(C=CC=1F)N1N=NC(=C1)CC=1N(N=CC=1)C Chemical compound ClC=1C=C(C=CC=1F)N1N=NC(=C1)CC=1N(N=CC=1)C OMQQLDITRYIEHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102100022645 Glutamate receptor ionotropic, NMDA 1 Human genes 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 150000001448 anilines Chemical class 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229960002994 dofetilide Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 125000005624 silicic acid group Chemical class 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- BCXOSCQTHVTUET-UHFFFAOYSA-N 1-(2-fluoro-5-nitrophenyl)ethanone Chemical compound CC(=O)C1=CC([N+]([O-])=O)=CC=C1F BCXOSCQTHVTUET-UHFFFAOYSA-N 0.000 description 2
- LFRONVXGXQDPSL-UHFFFAOYSA-N 1-(3-chloro-4-fluorophenyl)-4-(chloromethyl)triazole Chemical compound C1=C(Cl)C(F)=CC=C1N1N=NC(CCl)=C1 LFRONVXGXQDPSL-UHFFFAOYSA-N 0.000 description 2
- LUILKELNVBKKTG-ZOZJKLBQSA-N 1-[(1s,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol;methanesulfonic acid;trihydrate Chemical compound O.O.O.CS(O)(=O)=O.C1([C@H](O)[C@H](C)N2CCC(O)(CC2)C=2C=CC=CC=2)=CC=C(O)C=C1 LUILKELNVBKKTG-ZOZJKLBQSA-N 0.000 description 2
- HZVGOEUGZJFTNN-UHFFFAOYSA-N 1-azido-4-chlorobenzene Chemical compound ClC1=CC=C(N=[N+]=[N-])C=C1 HZVGOEUGZJFTNN-UHFFFAOYSA-N 0.000 description 2
- HLXOVAMYQUFLPE-UHFFFAOYSA-N 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CN1N=CC=C1B1OC(C)(C)C(C)(C)O1 HLXOVAMYQUFLPE-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- UKSAGCUNNXEOBJ-UHFFFAOYSA-N 2-(difluoromethoxy)-1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C(OC(F)F)=C1 UKSAGCUNNXEOBJ-UHFFFAOYSA-N 0.000 description 2
- VXIMQWWMIPNFEO-UHFFFAOYSA-N 2-(difluoromethyl)-1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C(C(F)F)=C1 VXIMQWWMIPNFEO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical class OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- PJUZQOULZWELPK-UHFFFAOYSA-N 4-(chloromethyl)-1-(4-chlorophenyl)triazole Chemical compound N1=NC(CCl)=CN1C1=CC=C(Cl)C=C1 PJUZQOULZWELPK-UHFFFAOYSA-N 0.000 description 2
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 2
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- UAWVRVFHMOSAPU-UHFFFAOYSA-N 7-chlorokynurenic acid Chemical compound C1=CC(Cl)=CC2=NC(C(=O)O)=CC(O)=C21 UAWVRVFHMOSAPU-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010008748 Chorea Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101150021949 GRIN1 gene Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 101710121995 Glutamate receptor ionotropic, NMDA 1 Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000034308 Grand mal convulsion Diseases 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001034045 Homo sapiens G protein-regulated inducer of neurite outgrowth 2 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010021750 Infantile Spasms Diseases 0.000 description 2
- 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 2
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 2
- 208000002033 Myoclonus Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 2
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 206010044074 Torticollis Diseases 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- CAHIFLPAMJOAGI-UHFFFAOYSA-N [1-(4-chlorophenyl)triazol-4-yl]methanol Chemical compound N1=NC(CO)=CN1C1=CC=C(Cl)C=C1 CAHIFLPAMJOAGI-UHFFFAOYSA-N 0.000 description 2
- 208000003554 absence epilepsy Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 210000001627 cerebral artery Anatomy 0.000 description 2
- 208000012601 choreatic disease Diseases 0.000 description 2
- 230000002566 clonic effect Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 208000026725 cyclothymic disease Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 201000002904 focal dystonia Diseases 0.000 description 2
- 230000000848 glutamatergic effect Effects 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229920006158 high molecular weight polymer Polymers 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- DEPDDPLQZYCHOH-UHFFFAOYSA-N imidazol-2-ylamine Natural products NC1=NC=CN1 DEPDDPLQZYCHOH-UHFFFAOYSA-N 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 229910052740 iodine Chemical group 0.000 description 2
- 239000011630 iodine Chemical group 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000020796 long term synaptic depression Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 230000002151 myoclonic effect Effects 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- KUNICNFETYAKKO-UHFFFAOYSA-N sulfuric acid;pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O KUNICNFETYAKKO-UHFFFAOYSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000003956 synaptic plasticity Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- SZHOJFHSIKHZHA-UHFFFAOYSA-N tridecanoic acid Chemical compound CCCCCCCCCCCCC(O)=O SZHOJFHSIKHZHA-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- NAUWTFJOPJWYOT-UHFFFAOYSA-N vanoxerine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)OCCN1CCN(CCCC=2C=CC=CC=2)CC1 NAUWTFJOPJWYOT-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 150000000177 1,2,3-triazoles Chemical class 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- RAQPOZGWANIDQT-UHFFFAOYSA-N 1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine Chemical compound C=1C=CC=CC=1CCCN(CC1)CCN1CCOC(C=1C=CC=CC=1)C1=CC=CC=C1 RAQPOZGWANIDQT-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XUJLWPFSUCHPQL-UHFFFAOYSA-N 11-methyldodecan-1-ol Chemical compound CC(C)CCCCCCCCCCO XUJLWPFSUCHPQL-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- LFHLEABTNIQIQO-UHFFFAOYSA-N 1H-isoindole Chemical compound C1=CC=C2CN=CC2=C1 LFHLEABTNIQIQO-UHFFFAOYSA-N 0.000 description 1
- MWFUQWJSIBEMPW-UHFFFAOYSA-N 1h-imidazol-2-yl-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)C1=NC=CN1 MWFUQWJSIBEMPW-UHFFFAOYSA-N 0.000 description 1
- IPDWABJNXLNLRA-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical class OC(=O)C(O)C(O)C(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IPDWABJNXLNLRA-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 description 1
- VFVHWCKUHAEDMY-UHFFFAOYSA-N 2-chloro-5-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(Cl)C(C=O)=C1 VFVHWCKUHAEDMY-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- WFRLFZAMCVAQLN-UHFFFAOYSA-N 2-fluoro-5-nitrophenol Chemical compound OC1=CC([N+]([O-])=O)=CC=C1F WFRLFZAMCVAQLN-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- LDZYRENCLPUXAX-UHFFFAOYSA-N 2-methyl-1h-benzimidazole Chemical compound C1=CC=C2NC(C)=NC2=C1 LDZYRENCLPUXAX-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- SDYWXFYBZPNOFX-UHFFFAOYSA-N 3,4-dichloroaniline Chemical compound NC1=CC=C(Cl)C(Cl)=C1 SDYWXFYBZPNOFX-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 1
- BNZAUKCPEARMKF-UHFFFAOYSA-N 3-fluoro-5-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC(F)=CC(C=O)=C1 BNZAUKCPEARMKF-UHFFFAOYSA-N 0.000 description 1
- MZGZUHNSMNNSRJ-UHFFFAOYSA-N 4-(pentafluoro-$l^{6}-sulfanyl)aniline Chemical compound NC1=CC=C(S(F)(F)(F)(F)F)C=C1 MZGZUHNSMNNSRJ-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- KWLOIDOKWUESNM-UHFFFAOYSA-N 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NN1 KWLOIDOKWUESNM-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 102000003678 AMPA Receptors Human genes 0.000 description 1
- 108090000078 AMPA Receptors Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 206010003628 Atonic seizures Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 238000003148 Calcium 5 Assay Kit Methods 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZBEZLTKSDKTNEM-UHFFFAOYSA-N Cc(cc1)ccc1C(c1ncc[n]1Cc1c[n](-c(cc2)ccc2Cl)nc1)=O Chemical compound Cc(cc1)ccc1C(c1ncc[n]1Cc1c[n](-c(cc2)ccc2Cl)nc1)=O ZBEZLTKSDKTNEM-UHFFFAOYSA-N 0.000 description 1
- DFMRLPKBAMEEHN-UHFFFAOYSA-N Cc1ccc[n]1Cc1c[n](-c(cc2)cc(C(F)F)c2F)nn1 Chemical compound Cc1ccc[n]1Cc1c[n](-c(cc2)cc(C(F)F)c2F)nn1 DFMRLPKBAMEEHN-UHFFFAOYSA-N 0.000 description 1
- XQCCHHFMEHGFNK-UHFFFAOYSA-N Cc1nc(C)n[n]1Cc1c[n](-c(cc2)ccc2N)nn1 Chemical compound Cc1nc(C)n[n]1Cc1c[n](-c(cc2)ccc2N)nn1 XQCCHHFMEHGFNK-UHFFFAOYSA-N 0.000 description 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- SDYVDXMMCZXDQX-UHFFFAOYSA-N ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)CCO)OC(F)F Chemical compound ClC1=C(C=C(C=C1)N1N=NC(=C1)CN1C(=NC=C1)CCO)OC(F)F SDYVDXMMCZXDQX-UHFFFAOYSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000033001 Complex partial seizures Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 229930195711 D-Serine Natural products 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000032538 Depersonalisation Diseases 0.000 description 1
- 206010012422 Derealisation Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012676 Diabetic mononeuropathy Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010073681 Epidural haemorrhage Diseases 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- UJPVZTKYGGHGLB-UHFFFAOYSA-N FC(C)(F)C=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)C Chemical compound FC(C)(F)C=1C=C(C=CC=1F)N1N=NC(=C1)CN1C(=NC=C1)C UJPVZTKYGGHGLB-UHFFFAOYSA-N 0.000 description 1
- QCJVMOHVFAZSQX-UHFFFAOYSA-N FC(F)C1=C(F)C=CC(=C1)N1C=C(CCl)N=N1 Chemical compound FC(F)C1=C(F)C=CC(=C1)N1C=C(CCl)N=N1 QCJVMOHVFAZSQX-UHFFFAOYSA-N 0.000 description 1
- FUFZNGNDYHCHJU-UHFFFAOYSA-N FC(F)C1=C(F)C=CC(=C1)N=[N+]=[N-] Chemical compound FC(F)C1=C(F)C=CC(=C1)N=[N+]=[N-] FUFZNGNDYHCHJU-UHFFFAOYSA-N 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 101710150822 G protein-regulated inducer of neurite outgrowth 1 Proteins 0.000 description 1
- 102100038942 Glutamate receptor ionotropic, NMDA 3A Human genes 0.000 description 1
- 101710195181 Glutamate receptor ionotropic, NMDA 3A Proteins 0.000 description 1
- 102100038958 Glutamate receptor ionotropic, NMDA 3B Human genes 0.000 description 1
- 101710195174 Glutamate receptor ionotropic, NMDA 3B Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000972850 Homo sapiens Glutamate receptor ionotropic, NMDA 2B Proteins 0.000 description 1
- 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 description 1
- 206010071081 Idiopathic generalised epilepsy Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 208000004404 Intractable Pain Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010071082 Juvenile myoclonic epilepsy Diseases 0.000 description 1
- 102000000079 Kainic Acid Receptors Human genes 0.000 description 1
- 108010069902 Kainic Acid Receptors Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- RGAPVBWYXMTMAW-UHFFFAOYSA-N NC1=CC=C([S])C=C1 Chemical compound NC1=CC=C([S])C=C1 RGAPVBWYXMTMAW-UHFFFAOYSA-N 0.000 description 1
- YEAWROBVHQCOOS-UHFFFAOYSA-N NC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC=CC=C1 Chemical class NC=1N(C=CN=1)CC=1N=NN(C=1)C1=CC=CC=C1 YEAWROBVHQCOOS-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 208000037158 Partial Epilepsies Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000012202 Pervasive developmental disease Diseases 0.000 description 1
- 206010034759 Petit mal epilepsy Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 206010039670 Sciatic nerve injury Diseases 0.000 description 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N Serotonin Natural products C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
- 206010040703 Simple partial seizures Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 206010067672 Spasmodic dysphonia Diseases 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 206010042364 Subdural haemorrhage Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000005247 Traumatic Brain Hemorrhage Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 201000006791 West syndrome Diseases 0.000 description 1
- 208000013142 Writer cramp Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000012826 adjustment disease Diseases 0.000 description 1
- 229960002629 agomelatine Drugs 0.000 description 1
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003935 attention Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000022257 bipolar II disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 206010008087 cerebral arteritis Diseases 0.000 description 1
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000006726 chronic neurodegeneration Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 230000006690 co-activation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 201000002342 diabetic polyneuropathy Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 229960002380 dibutyl phthalate Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical class COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 208000009985 drug-induced dyskinesia Diseases 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 201000002865 focal hand dystonia Diseases 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000000174 gluconic acid Chemical group 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000009939 hypertensive encephalopathy Diseases 0.000 description 1
- 230000001505 hypomanic effect Effects 0.000 description 1
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000018197 inherited torticollis Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 201000002901 multifocal dystonia Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- VLZLOWPYUQHHCG-UHFFFAOYSA-N nitromethylbenzene Chemical compound [O-][N+](=O)CC1=CC=CC=C1 VLZLOWPYUQHHCG-UHFFFAOYSA-N 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical class CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 201000002851 oromandibular dystonia Diseases 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940053544 other antidepressants in atc Drugs 0.000 description 1
- 229960002888 oxitriptan Drugs 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229960003770 reboxetine Drugs 0.000 description 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000036390 resting membrane potential Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- MRTAVLDNYYEJHK-UHFFFAOYSA-M sodium;2-chloro-2,2-difluoroacetate Chemical compound [Na+].[O-]C(=O)C(F)(F)Cl MRTAVLDNYYEJHK-UHFFFAOYSA-M 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 201000002849 spasmodic dystonia Diseases 0.000 description 1
- 208000012217 specific developmental disease Diseases 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- DPUOLQHDNGRHBS-MDZDMXLPSA-N trans-Brassidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-MDZDMXLPSA-N 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 210000001260 vocal cord Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462037831P | 2014-08-15 | 2014-08-15 | |
| US201562146656P | 2015-04-13 | 2015-04-13 | |
| PCT/US2015/045412 WO2016025917A1 (en) | 2014-08-15 | 2015-08-14 | Triazoles as nr2b receptor inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2791186T3 true ES2791186T3 (es) | 2020-11-03 |
Family
ID=54266608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15777754T Active ES2791186T3 (es) | 2014-08-15 | 2015-08-14 | Triazoles como inhibidores de receptores NR2B |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9981950B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3180329B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6605020B2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3180329T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2791186T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE049277T2 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3180329T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3180329T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016025917A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE49517E1 (en) | 2014-08-15 | 2023-05-02 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
| PT3180329T (pt) | 2014-08-15 | 2020-06-08 | Janssen Pharmaceuticals Inc | Triazóis como inibidores do recetor nr2b |
| HRP20200410T1 (hr) | 2015-07-09 | 2020-08-21 | Janssen Pharmaceutica Nv | Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora |
| CN109071488B (zh) | 2016-02-10 | 2021-08-13 | 詹森药业有限公司 | 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂 |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| IL267195B2 (en) | 2016-12-14 | 2024-05-01 | Sk Biopharmaceuticals Co Ltd | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder |
| US11447503B2 (en) | 2019-06-14 | 2022-09-20 | Janssen Pharmaceutica Nv | Pyridine carbamates and their use as GLUN2B receptor modulators |
| JP7346441B2 (ja) | 2018-04-04 | 2023-09-19 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピリジン及びピリミジン並びにｇｌｕｎ２ｂ受容体調節物質としてのそれらの使用 |
| MX2021015500A (es) | 2019-06-14 | 2022-02-10 | Janssen Pharmaceutica Nv | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. |
| CA3142998A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as glun2b receptor modulators |
| TW202112774A (zh) | 2019-06-14 | 2021-04-01 | 比利時商健生藥品公司 | 經取代之吡唑并－吡啶醯胺及其作為ｇｌｕｎ２ｂ受體調節劑之用途 |
| JP2022536424A (ja) | 2019-06-14 | 2022-08-16 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ヘテロ芳香族ピラゾロピリジン及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用 |
| KR20220020917A (ko) | 2019-06-14 | 2022-02-21 | 얀센 파마슈티카 엔.브이. | 치환된 피라졸로[4,3-b]피리딘 및 GLUN2B 수용체 조절제로서의 이들의 용도 |
| PH12021552839A1 (en) | 2019-06-14 | 2022-10-03 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610723B2 (en) * | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| EP1490364B1 (en) | 2002-03-28 | 2007-09-26 | Eisai R&D Management Co., Ltd. | 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders |
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| TW200604183A (en) | 2004-02-18 | 2006-02-01 | Astrazeneca Ab | Triazole compounds and their use as metabotropic glutamate receptor antagonists |
| US7807704B2 (en) | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| KR20100017372A (ko) | 2007-05-25 | 2010-02-16 | 애보트 게엠베하 운트 콤파니 카게 | 향대사성 글루타메이트 수용체 2（ｍｇｌｕ2 수용체）의 포지티브 조절자로서의 헤테로사이클릭 화합물 |
| EP2194045A4 (en) | 2007-08-30 | 2011-09-21 | Takeda Pharmaceutical | Substituted pyrazole derivative |
| EP2215073A4 (en) | 2007-10-31 | 2011-04-06 | Merck Sharp & Dohme | SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS |
| RU2499598C2 (ru) | 2008-03-27 | 2013-11-27 | Евотек Интернациональ Гмбх | Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов |
| WO2010016490A1 (ja) | 2008-08-05 | 2010-02-11 | 第一三共株式会社 | イミダゾピリジン－２－オン誘導体 |
| US9643922B2 (en) * | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| AU2009304293B2 (en) | 2008-10-16 | 2012-04-26 | Addex Pharma S.A. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| EP3037421A3 (en) | 2008-11-25 | 2016-11-30 | University Of Rochester | Mlk inhibitors and methods of use |
| WO2010108187A2 (en) * | 2009-03-20 | 2010-09-23 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| WO2011156245A2 (en) | 2010-06-09 | 2011-12-15 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mglur2 |
| WO2013130855A1 (en) | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| WO2014124651A1 (en) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists |
| EP2970200A1 (en) | 2013-03-13 | 2016-01-20 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
| PT3180329T (pt) | 2014-08-15 | 2020-06-08 | Janssen Pharmaceuticals Inc | Triazóis como inibidores do recetor nr2b |
| USRE49517E1 (en) | 2014-08-15 | 2023-05-02 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
| HRP20200410T1 (hr) | 2015-07-09 | 2020-08-21 | Janssen Pharmaceutica Nv | Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora |
| CN109071488B (zh) | 2016-02-10 | 2021-08-13 | 詹森药业有限公司 | 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂 |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
-
2015
- 2015-08-14 PT PT157777541T patent/PT3180329T/pt unknown
- 2015-08-14 WO PCT/US2015/045412 patent/WO2016025917A1/en not_active Ceased
- 2015-08-14 US US15/503,864 patent/US9981950B2/en active Active
- 2015-08-14 EP EP15777754.1A patent/EP3180329B1/en active Active
- 2015-08-14 DK DK15777754.1T patent/DK3180329T3/da active
- 2015-08-14 PL PL15777754T patent/PL3180329T3/pl unknown
- 2015-08-14 ES ES15777754T patent/ES2791186T3/es active Active
- 2015-08-14 HU HUE15777754A patent/HUE049277T2/hu unknown
- 2015-08-14 JP JP2017508504A patent/JP6605020B2/ja active Active
-
2018
- 2018-04-27 US US15/964,794 patent/US10323021B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9981950B2 (en) | 2018-05-29 |
| WO2016025917A1 (en) | 2016-02-18 |
| US10323021B2 (en) | 2019-06-18 |
| HUE049277T2 (hu) | 2020-09-28 |
| JP2017524019A (ja) | 2017-08-24 |
| US20180282305A1 (en) | 2018-10-04 |
| US20170226087A1 (en) | 2017-08-10 |
| EP3180329A1 (en) | 2017-06-21 |
| DK3180329T3 (da) | 2020-04-06 |
| JP6605020B2 (ja) | 2019-11-13 |
| PL3180329T3 (pl) | 2020-08-24 |
| EP3180329B1 (en) | 2020-03-18 |
| PT3180329T (pt) | 2020-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2791186T3 (es) | Triazoles como inhibidores de receptores NR2B | |
| ES2791252T3 (es) | Pirazoles | |
| AU2016384921B2 (en) | Crystalline form of BTK kinase inhibitor and preparation method thereof | |
| CA3076202A1 (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
| BR112021012186A2 (pt) | Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos | |
| JP2019535837A (ja) | 向精神薬およびその使用 | |
| KR101905295B1 (ko) | 나프티리딘디온 유도체 | |
| US12383544B2 (en) | Methods for the treatment of polycystic kidney disease | |
| BR112020001775A2 (pt) | composto e processo para a preparação do mesmo, composição farmacêutica. | |
| JP6941235B2 (ja) | イミダゾピリジン誘導体及び薬物としてのその使用 | |
| EP3700890B1 (en) | Alcoxyamino derivatives for treating pain and pain related conditions | |
| JP2008239546A (ja) | アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤 | |
| WO2022002859A1 (en) | Substituted n-phenylacetamides having p2x4 receptor antagonistic activity | |
| JP2008231027A (ja) | アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤 | |
| EP3873901A1 (en) | New alcoxyaminopyridine derivatives for treating pain and pain related conditions | |
| HK40037009A (en) | Alcoxyamino derivatives for treating pain and pain related conditions | |
| HK40037009B (en) | Alcoxyamino derivatives for treating pain and pain related conditions | |
| HK40033047B (en) | Imidazopyridine derivatives and the use thereof as medicament | |
| HK40033047A (en) | Imidazopyridine derivatives and the use thereof as medicament | |
| JP2014502993A (ja) | ＣａＶ２．２カルシウムチャンネルブロッカーとしてのピペラジン誘導体 |